Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Telegram Restored on Apple App Store After Temporary Removal 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Sanofi, the French pharmaceutical company, will be helping Moderna with the production of COVID-19 vaccines. The move was made in an effort to allow the American pharmaceutical and biotechnology firm to fulfill its orders and meet the demand for its shots.
Sanofi confirms production of Moderna shots
On Monday, April 26, Sanofi said that it has joined hands with the Massachusetts-headquartered biotech firm so it can provide assistance with filling vials and finish the packaging of up to 200 million doses as the demand for the Moderna COVID-19 vaccine is high.
Sanofi will be manufacturing the shots in its facility in Ridgefield, New Jersey. While the French company shared some info about its latest partnership with Moderna, it did not disclose any detail regarding the financial aspect of their deal, as per CNBC.
This is the third contract that Sanofi was able to secure since the start of this year. It previously signed a deal with Pfizer/BioNTech, to help them with supplying more than 125 million doses of coronavirus shots. The company also pledged to complete the filling and packing of Johnson & Johnson vaccines, and it must churn out at least 12 million doses per month.
Sanofi’s contribution in fulfilling Moderna’s COVID-19 vaccine supply will begin in September. While it has many deals to work on, the company is also busy in the development of its own vaccines in partnership with GlaxoSmithKline and another one with Translate Bio.
Sanofi aims to fill the bill for vaccines in the U.S.
The Wall Street Journal reported that based on the info coming from Sanofi’s spokesman, the finished doses of Moderna vaccines are for the U.S. supply where Moderna has an agreement until April 2022.
Meanwhile, Novartis AG and Merck Co. are also helping other makers of the coronavirus vaccines by forming agreements for production. The collaborations among the manufacturers are a collective effort to increase production so every nation in the world can have the doses they need.
Finally, Moderna is planning to distribute a total of 300 million doses of COVID-19 shots in the U.S. by the end of July. The delivery is projected to help President Biden achieve his goal of having the majority of American adults vaccinated by summer.
